122.61
price up icon0.67%   0.81
after-market Handel nachbörslich: 122.61
loading
Schlusskurs vom Vortag:
$121.80
Offen:
$122.65
24-Stunden-Volumen:
2.36M
Relative Volume:
1.60
Marktkapitalisierung:
$259.00B
Einnahmen:
$53.40B
Nettoeinkommen (Verlust:
$13.68B
KGV:
17.80
EPS:
6.8864
Netto-Cashflow:
$16.89B
1W Leistung:
-6.86%
1M Leistung:
-4.39%
6M Leistung:
+8.04%
1J Leistung:
+11.55%
1-Tages-Spanne:
Value
$121.98
$123.33
1-Wochen-Bereich:
Value
$121.57
$131.54
52-Wochen-Spanne:
Value
$96.06
$133.55

Novartis Ag Adr Stock (NVS) Company Profile

Name
Firmenname
Novartis Ag Adr
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
75,883
Name
Twitter
@novartis
Name
Nächster Verdiensttermin
2025-07-17
Name
Neueste SEC-Einreichungen
Name
NVS's Discussions on Twitter

Vergleichen Sie NVS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
122.61 233.71B 53.40B 13.68B 16.89B 6.8864
Drug Manufacturers - General icon
LLY
Lilly Eli Co
844.50 729.29B 53.26B 13.80B -50.20M 15.08
Drug Manufacturers - General icon
JNJ
Johnson Johnson
189.05 449.57B 92.15B 25.12B 20.46B 10.36
Drug Manufacturers - General icon
ABBV
Abbvie Inc
228.20 397.72B 58.33B 3.73B 18.24B 2.1013
Drug Manufacturers - General icon
MRK
Merck Co Inc
86.28 216.26B 63.43B 16.42B 14.72B 6.4861

Novartis Ag Adr Stock (NVS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-09-12 Herabstufung Goldman Neutral → Sell
2025-08-08 Hochstufung Morgan Stanley Underweight → Equal-Weight
2025-02-13 Herabstufung UBS Buy → Neutral
2025-02-12 Eingeleitet Morgan Stanley Underweight
2025-02-04 Hochstufung Deutsche Bank Hold → Buy
2024-12-04 Herabstufung HSBC Securities Hold → Reduce
2024-09-11 Herabstufung BofA Securities Buy → Neutral
2024-09-05 Herabstufung Goldman Buy → Neutral
2024-09-03 Herabstufung Jefferies Buy → Hold
2024-07-19 Herabstufung Deutsche Bank Buy → Hold
2024-05-30 Eingeleitet Goldman Buy
2024-02-23 Eingeleitet BMO Capital Markets Market Perform
2024-01-23 Eingeleitet Morgan Stanley Equal-Weight
2024-01-16 Fortgesetzt UBS Buy
2023-12-18 Herabstufung HSBC Securities Buy → Hold
2023-09-25 Hochstufung Morgan Stanley Underweight → Equal-Weight
2023-07-14 Eingeleitet HSBC Securities Buy
2023-04-26 Hochstufung Deutsche Bank Hold → Buy
2023-03-27 Hochstufung Deutsche Bank Sell → Hold
2023-01-26 Herabstufung Citigroup Buy → Neutral
2022-12-05 Hochstufung Stifel Hold → Buy
2022-09-15 Herabstufung Credit Suisse Neutral → Underperform
2022-09-14 Herabstufung Berenberg Buy → Hold
2022-05-09 Herabstufung Wolfe Research Outperform → Peer Perform
2022-01-10 Fortgesetzt Citigroup Buy
2021-12-14 Herabstufung Redburn Buy → Neutral
2021-12-06 Herabstufung Exane BNP Paribas Outperform → Neutral
2021-12-03 Herabstufung Bryan Garnier Buy → Neutral
2021-09-20 Herabstufung Deutsche Bank Hold → Sell
2021-03-22 Eingeleitet Bernstein Mkt Perform
2021-03-10 Herabstufung Argus Buy → Hold
2021-02-01 Herabstufung Cowen Outperform → Market Perform
2021-01-15 Eingeleitet Deutsche Bank Buy
2020-09-29 Eingeleitet Berenberg Buy
2020-09-10 Hochstufung UBS Neutral → Buy
2020-09-01 Hochstufung Morgan Stanley Equal-Weight → Overweight
2020-06-15 Hochstufung Citigroup Neutral → Buy
2020-03-10 Hochstufung Morgan Stanley Underweight → Equal-Weight
2020-02-25 Herabstufung Guggenheim Buy → Neutral
2019-04-25 Hochstufung Guggenheim Neutral → Buy
2019-04-25 Hochstufung Liberum Hold → Buy
2019-04-10 Herabstufung Morgan Stanley Equal-Weight → Underweight
2019-01-02 Herabstufung JP Morgan Neutral → Underweight
2018-12-11 Fortgesetzt Jefferies Buy
2018-10-09 Eingeleitet Guggenheim Neutral
2018-09-10 Hochstufung BofA/Merrill Underperform → Buy
2018-05-29 Herabstufung HSBC Securities Buy → Hold
2018-05-25 Hochstufung Credit Suisse Underperform → Neutral
2018-01-25 Bestätigt Leerink Partners Outperform
2017-12-06 Herabstufung BofA/Merrill Neutral → Underperform
2017-07-26 Hochstufung Morgan Stanley Underweight → Overweight
2017-07-05 Herabstufung Credit Suisse Neutral → Underperform
2017-03-09 Eingeleitet Liberum Buy
Alle ansehen

Novartis Ag Adr Aktie (NVS) Neueste Nachrichten

pulisher
Oct 29, 2025

Pharmaceutical Market to Reach USD 3,033.21 Billion by 2034 Driven by Rising Geriatric Population - GlobeNewswire Inc.

Oct 29, 2025
pulisher
Oct 29, 2025

Novartis' Strong Branded Drug Portfolio Supports Steady Long-Term Growth - Morningstar

Oct 29, 2025
pulisher
Oct 28, 2025

Novartis completes acquisition of Tourmaline Bio - Novartis

Oct 28, 2025
pulisher
Oct 28, 2025

Novartis ADR earnings missed by $0.02, revenue topped estimates - Investing.com Nigeria

Oct 28, 2025
pulisher
Oct 27, 2025

Novartis to acquire Avidity Biosciences in $12B deal - Proactive financial news

Oct 27, 2025
pulisher
Oct 27, 2025

Why Avidity Biosciences Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket - Benzinga

Oct 27, 2025
pulisher
Oct 22, 2025

Novartis Cosentyx Trial Shows Efficacy In Patients With Stiff Joints And Muscle Pain - Sahm

Oct 22, 2025
pulisher
Oct 22, 2025

Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer - Novartis

Oct 22, 2025
pulisher
Oct 20, 2025

Will Positive Regulatory Updates Further Boost INCY Stock? - The Globe and Mail

Oct 20, 2025
pulisher
Oct 17, 2025

Novartis Cancer Drug Shows Sustained Benefit In Five-Year Breast Cancer Trial - Sahm

Oct 17, 2025
pulisher
Oct 16, 2025

Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity - Sahm

Oct 16, 2025
pulisher
Oct 16, 2025

Novartis Strengthens Kidney Disease Pipeline With Promising Data - Sahm

Oct 16, 2025
pulisher
Oct 15, 2025

Next-Generation Targeted Therapies Reshape Precision Oncology Landscape - Sahm

Oct 15, 2025
pulisher
Oct 14, 2025

Vor Bio's Collaborator Delivers Positive Results For Telitacicept In Autoimmune Disorder That Impacts Tears - Sahm

Oct 14, 2025
pulisher
Oct 13, 2025

Will the Orbital Acquisition Strengthen BMY's Cell Therapy Portfolio? - The Globe and Mail

Oct 13, 2025
pulisher
Oct 11, 2025

UBS Reaffirms Their Hold Rating on Novartis AG (NOVN) - The Globe and Mail

Oct 11, 2025
pulisher
Oct 08, 2025

Should You Buy Novartis Stock Before October 28? - Barchart.com

Oct 08, 2025
pulisher
Oct 08, 2025

Barclays Reaffirms Their Sell Rating on Novartis AG (NOVN) - The Globe and Mail

Oct 08, 2025
pulisher
Oct 04, 2025

2 Surefire Dividend Stocks to Buy for the Long Haul - sharewise.com

Oct 04, 2025
pulisher
Oct 03, 2025

Novartis: Superstars Entresto And Kisqali Fuel Market Outperformance (NYSE:NVS) - Seeking Alpha

Oct 03, 2025
pulisher
Sep 30, 2025

Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU) - Ariva

Sep 30, 2025
pulisher
Sep 29, 2025

Pharma's Direct-To-Patient Wave Hits Novartis Next - Sahm

Sep 29, 2025
pulisher
Sep 29, 2025

Novartis announces commencement of tender offer to acquire Tourmaline Bio - Novartis

Sep 29, 2025
pulisher
Sep 25, 2025

Trump's New Tariff Barrage Targets Drugs, Trucks, Cabinets: President Says Move Will Protect Manufacturers From 'Unfair Outside Competition' - Sahm

Sep 25, 2025
pulisher
Sep 25, 2025

Eli Lilly Stock Is Trading Down Thursday: What's Behind The Move? - Sahm

Sep 25, 2025
pulisher
Sep 24, 2025

Novartis, AbbVie Face Legal Defeat Over 340B Contract Pharmacies - Sahm

Sep 24, 2025
pulisher
Sep 19, 2025

INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream - The Globe and Mail

Sep 19, 2025
pulisher
Sep 15, 2025

Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments - Sahm

Sep 15, 2025
pulisher
Sep 13, 2025

Novartis (NVS) was downgraded to a Sell Rating at Goldman Sachs - The Globe and Mail

Sep 13, 2025
pulisher
Sep 12, 2025

Goldman Sachs Downgrades Novartis (NVS) to Sell Over Risk Concer - GuruFocus

Sep 12, 2025

Finanzdaten der Novartis Ag Adr-Aktie (NVS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
drug_manufacturers_general MRK
$86.28
price down icon 0.35%
drug_manufacturers_general NVO
$50.04
price down icon 2.59%
$292.00
price up icon 0.08%
$118.44
price down icon 0.05%
drug_manufacturers_general PFE
$24.29
price up icon 0.00%
Kapitalisierung:     |  Volumen (24h):